Validation of a web-based tool to predict the ipsilateral breast tumor recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients

Seung Pil Jung, Sung Mo Hur, Se Kyung Lee, Sangmin Kim, Min Young Choi, Soo Youn Bae, Jiyoung Kim, Min Kuk Kim, Won Ho Kil, Jun Ho Choe, Jung Han Kim, Jee Soo Kim, Seok Jin Nam, Jeoung Won Bae, Jeong Eon Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: IBTR! 2.0 is a web-based nomogram that predicts the 10-year ipsilateral breast tumor recurrence (IBTR) rate after breast-conserving therapy. We validated this nomogram in Korean patients. Methods: The nomogram was tested for 520 Korean patients, who underwent breast-conserving surgery followed by radiation therapy. Predicted and observed 10-year outcomes were compared for the entire cohort and for each group, predefined by nomogram-predicted risks: group 1, <3%; group 2, 3% to 5%; group 3, 5% to 10%; group 4, >10%. Results: In overall patients, the overall 10 year predicted and observed estimates of IBTR were 5.22% and 5.70% (p=0.68). In group 1, (n=124), the predicted and observed estimates were 2.25% and 1.80% (p=0.73), in group 2 (n=177), 3.95% and 3.90% (p=0.97), in group 3 (n=181), 7.14% and 8.80% (p=0.42), and in group 4 (n=38), 11.66% and 14.90% (p=0.73), respectively. Conclusion: In a previous validation of this nomogram based on American patients, nomogram-predicted IBTR rates were overestimated in the high-risk subgroup. However, our results based on Korean patients showed that the observed IBTR was higher than the predicted estimates in groups 3 and 4. This difference may arise from ethnic differences, as well as from the methods used to detect IBTR and the healthcare environment. IBTR! 2.0 may be considered as an acceptable nomogram in Korean patients with low- to moderate-risk of in-breast recurrence. Before widespread use of this nomogram, the IBTR! 2.0 needs a larger validation study and continuous modification.

Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalJournal of Breast Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Nomograms
Breast
Breast Neoplasms
Recurrence
Therapeutics
Segmental Mastectomy
Validation Studies
Radiotherapy
Delivery of Health Care

Keywords

  • Breast neoplasms
  • Nomograms
  • Radiotherapy
  • Recurrence
  • Validation studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Validation of a web-based tool to predict the ipsilateral breast tumor recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients. / Jung, Seung Pil; Hur, Sung Mo; Lee, Se Kyung; Kim, Sangmin; Choi, Min Young; Bae, Soo Youn; Kim, Jiyoung; Kim, Min Kuk; Kil, Won Ho; Choe, Jun Ho; Kim, Jung Han; Kim, Jee Soo; Nam, Seok Jin; Bae, Jeoung Won; Lee, Jeong Eon.

In: Journal of Breast Cancer, Vol. 16, No. 1, 01.03.2013, p. 97-103.

Research output: Contribution to journalArticle

Jung, SP, Hur, SM, Lee, SK, Kim, S, Choi, MY, Bae, SY, Kim, J, Kim, MK, Kil, WH, Choe, JH, Kim, JH, Kim, JS, Nam, SJ, Bae, JW & Lee, JE 2013, 'Validation of a web-based tool to predict the ipsilateral breast tumor recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients', Journal of Breast Cancer, vol. 16, no. 1, pp. 97-103. https://doi.org/10.4048/jbc.2013.16.1.97
Jung, Seung Pil ; Hur, Sung Mo ; Lee, Se Kyung ; Kim, Sangmin ; Choi, Min Young ; Bae, Soo Youn ; Kim, Jiyoung ; Kim, Min Kuk ; Kil, Won Ho ; Choe, Jun Ho ; Kim, Jung Han ; Kim, Jee Soo ; Nam, Seok Jin ; Bae, Jeoung Won ; Lee, Jeong Eon. / Validation of a web-based tool to predict the ipsilateral breast tumor recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients. In: Journal of Breast Cancer. 2013 ; Vol. 16, No. 1. pp. 97-103.
@article{ec7771f10b2840d98889d58bd0631871,
title = "Validation of a web-based tool to predict the ipsilateral breast tumor recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients",
abstract = "Purpose: IBTR! 2.0 is a web-based nomogram that predicts the 10-year ipsilateral breast tumor recurrence (IBTR) rate after breast-conserving therapy. We validated this nomogram in Korean patients. Methods: The nomogram was tested for 520 Korean patients, who underwent breast-conserving surgery followed by radiation therapy. Predicted and observed 10-year outcomes were compared for the entire cohort and for each group, predefined by nomogram-predicted risks: group 1, <3{\%}; group 2, 3{\%} to 5{\%}; group 3, 5{\%} to 10{\%}; group 4, >10{\%}. Results: In overall patients, the overall 10 year predicted and observed estimates of IBTR were 5.22{\%} and 5.70{\%} (p=0.68). In group 1, (n=124), the predicted and observed estimates were 2.25{\%} and 1.80{\%} (p=0.73), in group 2 (n=177), 3.95{\%} and 3.90{\%} (p=0.97), in group 3 (n=181), 7.14{\%} and 8.80{\%} (p=0.42), and in group 4 (n=38), 11.66{\%} and 14.90{\%} (p=0.73), respectively. Conclusion: In a previous validation of this nomogram based on American patients, nomogram-predicted IBTR rates were overestimated in the high-risk subgroup. However, our results based on Korean patients showed that the observed IBTR was higher than the predicted estimates in groups 3 and 4. This difference may arise from ethnic differences, as well as from the methods used to detect IBTR and the healthcare environment. IBTR! 2.0 may be considered as an acceptable nomogram in Korean patients with low- to moderate-risk of in-breast recurrence. Before widespread use of this nomogram, the IBTR! 2.0 needs a larger validation study and continuous modification.",
keywords = "Breast neoplasms, Nomograms, Radiotherapy, Recurrence, Validation studies",
author = "Jung, {Seung Pil} and Hur, {Sung Mo} and Lee, {Se Kyung} and Sangmin Kim and Choi, {Min Young} and Bae, {Soo Youn} and Jiyoung Kim and Kim, {Min Kuk} and Kil, {Won Ho} and Choe, {Jun Ho} and Kim, {Jung Han} and Kim, {Jee Soo} and Nam, {Seok Jin} and Bae, {Jeoung Won} and Lee, {Jeong Eon}",
year = "2013",
month = "3",
day = "1",
doi = "10.4048/jbc.2013.16.1.97",
language = "English",
volume = "16",
pages = "97--103",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "1",

}

TY - JOUR

T1 - Validation of a web-based tool to predict the ipsilateral breast tumor recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients

AU - Jung, Seung Pil

AU - Hur, Sung Mo

AU - Lee, Se Kyung

AU - Kim, Sangmin

AU - Choi, Min Young

AU - Bae, Soo Youn

AU - Kim, Jiyoung

AU - Kim, Min Kuk

AU - Kil, Won Ho

AU - Choe, Jun Ho

AU - Kim, Jung Han

AU - Kim, Jee Soo

AU - Nam, Seok Jin

AU - Bae, Jeoung Won

AU - Lee, Jeong Eon

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Purpose: IBTR! 2.0 is a web-based nomogram that predicts the 10-year ipsilateral breast tumor recurrence (IBTR) rate after breast-conserving therapy. We validated this nomogram in Korean patients. Methods: The nomogram was tested for 520 Korean patients, who underwent breast-conserving surgery followed by radiation therapy. Predicted and observed 10-year outcomes were compared for the entire cohort and for each group, predefined by nomogram-predicted risks: group 1, <3%; group 2, 3% to 5%; group 3, 5% to 10%; group 4, >10%. Results: In overall patients, the overall 10 year predicted and observed estimates of IBTR were 5.22% and 5.70% (p=0.68). In group 1, (n=124), the predicted and observed estimates were 2.25% and 1.80% (p=0.73), in group 2 (n=177), 3.95% and 3.90% (p=0.97), in group 3 (n=181), 7.14% and 8.80% (p=0.42), and in group 4 (n=38), 11.66% and 14.90% (p=0.73), respectively. Conclusion: In a previous validation of this nomogram based on American patients, nomogram-predicted IBTR rates were overestimated in the high-risk subgroup. However, our results based on Korean patients showed that the observed IBTR was higher than the predicted estimates in groups 3 and 4. This difference may arise from ethnic differences, as well as from the methods used to detect IBTR and the healthcare environment. IBTR! 2.0 may be considered as an acceptable nomogram in Korean patients with low- to moderate-risk of in-breast recurrence. Before widespread use of this nomogram, the IBTR! 2.0 needs a larger validation study and continuous modification.

AB - Purpose: IBTR! 2.0 is a web-based nomogram that predicts the 10-year ipsilateral breast tumor recurrence (IBTR) rate after breast-conserving therapy. We validated this nomogram in Korean patients. Methods: The nomogram was tested for 520 Korean patients, who underwent breast-conserving surgery followed by radiation therapy. Predicted and observed 10-year outcomes were compared for the entire cohort and for each group, predefined by nomogram-predicted risks: group 1, <3%; group 2, 3% to 5%; group 3, 5% to 10%; group 4, >10%. Results: In overall patients, the overall 10 year predicted and observed estimates of IBTR were 5.22% and 5.70% (p=0.68). In group 1, (n=124), the predicted and observed estimates were 2.25% and 1.80% (p=0.73), in group 2 (n=177), 3.95% and 3.90% (p=0.97), in group 3 (n=181), 7.14% and 8.80% (p=0.42), and in group 4 (n=38), 11.66% and 14.90% (p=0.73), respectively. Conclusion: In a previous validation of this nomogram based on American patients, nomogram-predicted IBTR rates were overestimated in the high-risk subgroup. However, our results based on Korean patients showed that the observed IBTR was higher than the predicted estimates in groups 3 and 4. This difference may arise from ethnic differences, as well as from the methods used to detect IBTR and the healthcare environment. IBTR! 2.0 may be considered as an acceptable nomogram in Korean patients with low- to moderate-risk of in-breast recurrence. Before widespread use of this nomogram, the IBTR! 2.0 needs a larger validation study and continuous modification.

KW - Breast neoplasms

KW - Nomograms

KW - Radiotherapy

KW - Recurrence

KW - Validation studies

UR - http://www.scopus.com/inward/record.url?scp=84876095894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876095894&partnerID=8YFLogxK

U2 - 10.4048/jbc.2013.16.1.97

DO - 10.4048/jbc.2013.16.1.97

M3 - Article

VL - 16

SP - 97

EP - 103

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 1

ER -